GE Spin-Off Wins US Approval For Prostate Cancer PET Tracer
This article was originally published in Clinica
Executive Summary
Two years after being spun out of GE Healthcare’s PET imaging division, Blue Earth Diagnostics (BED) is poised to take its Axumin molecular imaging agent to the US prostate cancer market following FDA approval.